Last reviewed · How we verify
kallikrein
kallikrein is a Small molecule drug developed by Techpool Bio-Pharma Co., Ltd.. It is currently FDA-approved. Also known as: KLK, Human urinary kallikrein, Human urinary kallidinogenase.
Kallikrein is a subgroup of serine proteases that can cleave peptide bonds in proteins. It has been studied in various clinical trials for conditions such as prostatic neoplasms, acute ischemic stroke, and hereditary angioedema, often in combination with other treatments like docetaxel and prednisone.
At a glance
| Generic name | kallikrein |
|---|---|
| Also known as | KLK, Human urinary kallikrein, Human urinary kallidinogenase |
| Sponsor | Techpool Bio-Pharma Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (PHASE2, PHASE3)
- Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke (NA)
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (PHASE3)
- A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer (PHASE1)
- A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (PHASE1)
- A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC (PHASE1, PHASE2)
- Berotralstat Treatment in Children With Hereditary Angioedema (PHASE3)
- An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- kallikrein CI brief — competitive landscape report
- kallikrein updates RSS · CI watch RSS
- Techpool Bio-Pharma Co., Ltd. portfolio CI
Frequently asked questions about kallikrein
What is kallikrein?
Who makes kallikrein?
Is kallikrein also known as anything else?
What development phase is kallikrein in?
Related
- Manufacturer: Techpool Bio-Pharma Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: KLK, Human urinary kallikrein, Human urinary kallidinogenase
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing